The Pan-Canadian Oncology Drug Review (pCODR) will be considering an application for the drug Everolimus (Afinitor) indicated for Gastrointestinal and Lung Neuroendocrine (NET) Tumours. Everolimus is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. Patient input is very important within this process to determine if a drug should be publicly funded. The Review process also looks at clinical evidence of efficacy, safety and effectiveness, relative therapeutic advantages and cost effectiveness. Your input may help to improve access to this new indication for this drug for NET patients.
CNETS Canada will make a submission to pCODR on behalf of patients as part of this review process. NET patients who have gastrointestinal or Lung NET Cancer have the option of completing a survey or participating in an interview. We are interested in the patient experience with Everolimus (Afinitor). Your responses are anonymous and confidential and will be used to identify common themes for the review. There is also a caregiver survey as pCODR is interested in this perspective as well.
Canadian as well as international patients and caregivers are invited to participate in the survey.
The survey is to be completed online through SurveyMonkey.
If you are a patient, click HERE. If you are a caregiver, click HERE.
Please complete the survey no later than May 15, 2016. If you are interested in being interviewed, please contact Sue Folinsbee at sue.folinsbee@cnetscanada.org. The interview is confidential and anonymous and will take 30 minutes.
CNETS Canada thanks you for your support. Access to publicly funded drugs that may improve clinical outcomes is critical to quality patient care.